Zepp Health (ZEPP) Q2 2026 earnings review
Growth Hits a Wall as OpEx Destroys Operating Leverage
Zepp's turnaround story is losing momentum. Revenue growth is severely decelerating, dropping from 78.5% in 25Q3 to just 6.9% this quarter, and guidance implies a YoY contraction for Q3. While management successfully shifted the mix toward premium products to maintain a stable 37.4% gross margin, this operational win was entirely eclipsed by a 51% surge in Selling & Marketing expenses. The aggressive spend widened the net loss to $11.3M. The narrative of achieving sustainable profitability is now highly questionable as top-line growth stalls while costs accelerate.
🐂 Bull Case
The mix shift is working. The high-end T-Rex series and the new Balance generation are commanding significantly higher ASPs (up to $599) without cannibalizing legacy volumes, proving Zepp's pricing ladder is viable.
Despite widening losses, tight working capital management allowed cash and equivalents to grow sequentially to $106.3M. Debt levels remain stable, reducing immediate liquidity risks.
🐻 Bear Case
The Q3 revenue guidance of $68-$73M implies a ~7% year-over-year decline. The explosive 40-70% growth rates of late 2025 were a temporary restocking and product-cycle anomaly, not a structural new baseline.
Management cannot cut a path to profitability while growing Selling & Marketing expenses at 7x the rate of revenue growth. Customer acquisition costs are cannibalizing all gross margin gains.
⚖️ Verdict: 🔴
Bearish. Decelerating revenue, a negative forward guide, and a blowout in marketing costs contradict management's narrative of disciplined, profitable growth. The premiumization strategy is working, but it isn't enough to carry the bottom line.
Key Themes
Q3 Growth Reversing to Contraction
The most glaring red flag is Q3 guidance. Management expects $68.0-$73.0M in revenue. Compared to $75.8M in 25Q3, this implies a reversing trend into a ~7% year-over-year contraction. Management blames a 'high comparison base' and delayed production ramps, but it signals the end of the hyper-growth recovery phase seen over the last year.
Data Contradicts Cost Control Narrative
Management claims to be 'disciplined in managing our expenses,' yet the data tells a different story. Selling and Marketing expenses accelerated rapidly, jumping 51% YoY (from $12.1M to $18.3M). This massive spend outpaced the meager 6.9% revenue growth and was the primary driver of the widened $12.3M operating loss. The operating leverage is actively deteriorating.
Premium T-Rex Mix Expanding ASP
Zepp is successfully convincing customers to pay more. The T-Rex 3 Pro ($399) and T-Rex Ultra 2 ($549) now account for roughly 50% of the entire T-Rex family's global activations. This proves that Zepp's software ecosystem and hardware durability can command legitimate premium pricing, defending gross margins.
Winning the $169 Price Tier
The Active series successfully carved out a new $169 price tier that didn't exist last year. This tier skyrocketed from ~22% of global Active family activations in Q1 to ~57% by late August. This successfully bridges the gap between ultra-budget trackers and the premium T-Rex lines.
Aggressive Pricing Actions Scheduled
In a rare display of pricing power, Zepp announced it will raise prices across the entire Bip family starting in January 2027. Demand for the 17-month-old Bip 6 remains so strong that management is willing to risk volume to improve unit economics. If successful, this will provide a direct injection to gross margins next year.
Macro: Memory Costs and FX Squeezing Margins
Despite a vastly improved product mix, gross margin only expanded 1.2% YoY (and actually moderated from 37.7% in Q1). The primary culprits are macroeconomic: soaring memory component costs and severe foreign-exchange headwinds (RMB appreciation). These external factors are effectively neutralizing Zepp's internal premiumization efforts.
Other KPIs
Stable YoY (up from 36.2%), but decelerating sequentially from Q1's 37.7% and heavily down from Q4's peak of 40.4%. The mix shift toward the higher-end Balance and T-Rex lines prevented severe margin compression from rising DDR memory costs, but the overall trajectory is plateauing.
A bright spot. Cash balances increased sequentially from $103.2 million in Q1, despite the $11.3M net loss. This highlights strong working capital execution, primarily through better inventory management (inventory remained flat at $62.4M).
Guidance
Reversing. At the $70.5M midpoint, this implies a 7% year-over-year revenue decline compared to $75.8M in 25Q3. Management cites a tough comparison base and launch timing, but this marks a severe break in the growth narrative established over the last four quarters.
Key Questions
S&M ROI Timeline
Selling and marketing expenses surged over 50% year-over-year, yet Q3 guidance implies negative revenue growth. How long will you tolerate this disconnect before cutting ad spend, and what is the expected ROI timeline on these new athlete and HYROX sponsorships?
Bip Price Hike Elasticity
You announced a price increase for the Bip family starting in January 2027. Have you modeled the expected volume elasticity, and are you willing to accept lower overall segment revenue to protect unit economics?
Memory Cost Outlook
You cited rising memory costs as a persistent headwind masking your gross margin improvements. Have these component costs peaked, or do you expect them to further compress margins in the back half of the year?